Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Allergen Inhalation on Adenosine Receptor Expression in Sputum and Peripheral Blood

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00116311
Recruitment Status : Unknown
Verified March 2007 by Groningen Research Institute for Asthma and COPD.
Recruitment status was:  Active, not recruiting
First Posted : June 29, 2005
Last Update Posted : March 21, 2007
Sponsor:
Information provided by:
Groningen Research Institute for Asthma and COPD

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The purpose of this study is to determine whether asthmatics have different adenosine receptor expression profiles than healthy controls. We hypothesize that asthmatics will have increased adenosine receptor expression versus control subjects.

We also want to study the effects of allergen inhalation on adenosine receptor expression in asthmatics. We believe that adenosine receptor expression will be upregulated after allergen inhalation.

Both hypotheses are being tested in sputum and peripheral blood.


Condition or disease Intervention/treatment
Asthma Healthy Behavioral: allergen inhalation Behavioral: withdrawal of medication Procedure: sputum induction

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Enrollment : 20 participants
Observational Model: Defined Population
Time Perspective: Other
Official Title: Effects of Allergen Inhalation on Adenosine Receptor Expression and Mast Cell Activation in Peripheral Blood and Sputum of Asthmatics and Healthy Subjects
Study Start Date : July 2005
Study Completion Date : February 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
Drug Information available for: Adenosine

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Asthmatic Subjects - Inclusion Criteria:

  • Clinical diagnosis of asthma
  • Steroid naive or subjects not using their inhaled steroids for the last 4 weeks, short-acting beta-agonist for rescue medication
  • FEV1 > 70% of predicted
  • Positive skin prick test for house dust mite, cat or grass pollen
  • PC20 methacholine or histamine < 8 mg/ml

Asthmatic Subjects - Exclusion Criteria:

  • Use of systemic steroids in the previous 6 weeks
  • Asthma exacerbations in the previous 6 weeks
  • Current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago

Healthy Subjects - Inclusion Criteria:

  • No airway complaints
  • FEV1 > 90% of predicted
  • Negative skin prick test
  • PC20 methacholine or histamine > 8 mg/ml

Healthy Subjects - Exclusion Criteria:

  • Use of steroids in the previous 6 weeks
  • Current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00116311


Locations
Layout table for location information
Netherlands
University Medical Center Groningen, Department of Pulmonology
Groningen, Netherlands, 9713 GZ
Sponsors and Collaborators
Groningen Research Institute for Asthma and COPD
Investigators
Layout table for investigator information
Principal Investigator: Dirkje S Postma, prof. MD PhD University Medical Center Groningen, Department of Pulmonology, hanzeplein 1, 9713 GZ Groningen, The Netherlands
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00116311    
Other Study ID Numbers: METc2004-253
First Posted: June 29, 2005    Key Record Dates
Last Update Posted: March 21, 2007
Last Verified: March 2007
Keywords provided by Groningen Research Institute for Asthma and COPD:
Adenosine receptors
asthma
sputum
peripheral blood
healthy
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Respiratory Aspiration
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Respiration Disorders
Pathologic Processes